TY - JOUR
T1 - Serum biomarkers for Alzheimer's disease
T2 - Proteomic discovery
AU - German, Dwight C.
AU - Gurnani, Prem
AU - Nandi, Animesh
AU - Garner, Harold R.
AU - Fisher, Wayne
AU - Diaz-Arrastia, Ramon
AU - O'Suilleabhain, Padraig
AU - Rosenblatt, Kevin P.
N1 - Funding Information:
The authors would like to thank Dr Terry Bottiglieri and Ms Carol Moore for technical assistance with the serum samples. Research supported by grants from the NIA (5P30 AG 012300-13), NIH/NIAID grant U54AI057156 (Western Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research), NIH/NHLBI PGA grant N01HV028185 (Center for Proteomics Research at UT Southwestern Medical Center), NIH/NCI grant P50 CA 70907-08 (UT Southwestern Medical Center/MD Anderson Cancer Center SPORE), grants AG025326-01, AG19712-5, and NSF Grant No. 0612214.
PY - 2007/8
Y1 - 2007/8
N2 - For Alzheimer's disease (AD), the most common neurodegenerative disease, there is no simple, cost-effective biomarker for disease identification. Using novel mass spectrometry (MS)-based techniques, and analysis of the albumin-enriched low molecular weight proteome, minute amounts of human serum were analyzed for the measurement of thousands of peptides and proteins in parallel. The mass spectrograms were then evaluated with a novel computer algorithm to identify spectral peaks that discriminate between samples from patients with and without AD. There are four peaks that distinguish AD from control subjects and AD subjects from those with Parkinson's disease (PD). Additionally, after analyzing data from a recently published study of AD and control subjects, we found three discriminating peaks in common with the four from our patient serum samples. The identification of these peptides/proteins, and their direct measurement in patient serum, may allow the development of a simple, cost-effective test for AD.
AB - For Alzheimer's disease (AD), the most common neurodegenerative disease, there is no simple, cost-effective biomarker for disease identification. Using novel mass spectrometry (MS)-based techniques, and analysis of the albumin-enriched low molecular weight proteome, minute amounts of human serum were analyzed for the measurement of thousands of peptides and proteins in parallel. The mass spectrograms were then evaluated with a novel computer algorithm to identify spectral peaks that discriminate between samples from patients with and without AD. There are four peaks that distinguish AD from control subjects and AD subjects from those with Parkinson's disease (PD). Additionally, after analyzing data from a recently published study of AD and control subjects, we found three discriminating peaks in common with the four from our patient serum samples. The identification of these peptides/proteins, and their direct measurement in patient serum, may allow the development of a simple, cost-effective test for AD.
KW - Albumin-bound fraction
KW - Biomarkers
KW - MALDI O-TOF
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=34547813002&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547813002&partnerID=8YFLogxK
U2 - 10.1016/j.biopha.2007.05.009
DO - 10.1016/j.biopha.2007.05.009
M3 - Article
C2 - 17614251
AN - SCOPUS:34547813002
VL - 61
SP - 383
EP - 389
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
SN - 0753-3322
IS - 7
ER -